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DEAR EDITOR
We appreciate your interest in our article and the suggestions 
for the enhancement of its publication.
In our study, we report the frequency of adverse effects 
in 43.1% of the patients treated with infliximab at 5 centers 
of pediatric rheumatology, which is in agreement with some 
reports in the literature, showing a rate up to 50% in pediatric 
patients.1-3 
Of the 58 patients analyzed in this study, 25 presented 
infusion adverse effects, and medication had to be discontinued 
in 17 patients because there was evidence of severe allergic 
reactions. Those patients did not receive infliximab again and 
migrated to another anti-TNF agent. Six patients who had mild 
reactions (flush, dyspnea, tachycardia, nausea) received this 
drug again with reduction of infusion speed. Four of them had 
reactions in the following applications and medication had to be 
discontinued. The other two patients continued with infliximab 
without complications.
The use of methotrexate may reduce the frequency of 
adverse effects4 and the literature reports its use associated with 
an anti-TNF agent not only to reduce adverse effects related 
to a lower production of antiinfliximab antibodies, but also to 
increase the efficiency of the treatment. Forty-nine patients 
had already used methotrexate before infliximab indication; 
17 out of them (34.7%) had reactions during infusion. Of the 
nine patients who had not been receiving methotrexate, 6 
(67%) had reaction, which confirms methotrexate protected 
some patients from adverse effects. Twenty seven patients 
had been using corticosteroid and 17 of them presented 
reaction during infliximab infusion. Thirteen patients who 
had adverse reactions were using both drugs (corticosteroid 
and methotrexate). 
The presence of antinuclear antibodies may predict an 
increasing risk of infusion reactions in adults with rheumatoid 
arthritis;4 however, we did not find any association with the 
presence of those antibodies nor higher frequency of infusion 
reactions in our patients.
Infliximab is a therapy option for patients with refractory 
disease and/or intolerance to maximum doses of methotrexate, 
but its application should be performed in a place equipped for 
urgency care and with trained personnel.
Sincerely,
Cássia M. Passarelli Lupoli Barbosa et al.
Pediatric Rheumatologist – Universidade Federal de São Paulo
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